



ASX Announcement | 11 November 2019

Adjournment of Scheme Meetings

11 November 2019 - Creso Pharma Limited (ASX:CPH) (“Creso Pharma” or “the Company”) confirms that the Share Scheme Meeting and the Option Scheme Meeting scheduled for today at 10:00am and 10:30am WST respectively were adjourned by the chairperson.

Unless otherwise advised, the meetings will be reconvened as follows:

- (a) Share Scheme Meeting - 10:00am WST
- (b) Option Scheme Meeting - the later of the conclusion of the Share Scheme Meeting and 10:15am WST,

on Monday 18 November 2019 at Level 4, 16 Milligan St, Perth 6000.

Ends.

Investor Enquiries

EverBlu Capital
E: info@everblucapital.com
P: +61 2 8249 0000

Media Enquiries

Julia Maguire | The Capital Network
E: julia@thecapitalnetwork.com.au
P: +61 419 815 386

About Creso Pharma

www.cresopharma.com

Creso Pharma brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp de-rived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso Pharma uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.



Forward looking statements

This announcement contains forward-looking statements with respect to Creso Pharma and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso Pharma could differ materially from those expressed or implied by such statements.

Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso Pharma and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso Pharma has no obligation to up-date such statements, except to the extent required by applicable laws.